YOKOHAMA CITY UNIVERSITY
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1882-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.yokohama-cu.ac.jp
Clinical Trials
219
Active:2
Completed:121
Trial Phases
5 Phases
Phase 1:5
Phase 2:19
Phase 3:2
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (218 trials with phase data)• Click on a phase to view related trials
Not Applicable
188 (86.2%)Phase 2
19 (8.7%)Phase 1
5 (2.3%)Phase 4
4 (1.8%)Phase 3
2 (0.9%)Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease
Phase 2
Active, not recruiting
- Conditions
- Non Alcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Yokohama City University
- Target Recruit Count
- 360
- Registration Number
- NCT06623539
- Locations
- 🇯🇵
Yokohama city university, Yokohama, Kanagawa, Japan
Elobixibat for Chronic Constipation Without Defecation Desire
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Yokohama City University
- Target Recruit Count
- 40
- Registration Number
- NCT05165199
- Locations
- 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan
Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
Phase 2
Active, not recruiting
- Conditions
- Nonalcoholic Fatty LiverNonalcoholic Steatohepatitis
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Yokohama City University
- Target Recruit Count
- 29
- Registration Number
- NCT05084404
- Locations
- 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan
Long-term Elobixibat for Chronic Constipation
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Yokohama City University
- Target Recruit Count
- 100
- Registration Number
- NCT04784780
- Locations
- 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
Phase 2
Completed
- Conditions
- Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver
- Interventions
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Yokohama City University
- Target Recruit Count
- 102
- Registration Number
- NCT04235205
- Locations
- 🇯🇵
Yokohama City University, Yokohama, Kanagawa, Japan
- Prev
- 1
- 2
- Next
News
No news found